XML 82 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8
Significant Accounting Policies (Details) (USD $)
3 Months Ended 6 Months Ended 0 Months Ended 6 Months Ended 1 Months Ended 6 Months Ended 7 Months Ended 6 Months Ended 3 Months Ended 12 Months Ended 1 Months Ended 3 Months Ended
Jun. 30, 2013
Jun. 30, 2012
Jun. 30, 2013
Jun. 30, 2012
Oct. 31, 2012
GSK
Convertible notes guarantee obligation
Regulus
security
Jun. 30, 2013
Collaborations
item
Jun. 30, 2013
Collaborations
New development candidate
Minimum
Jun. 30, 2013
Collaborations
New development candidate
Maximum
Jun. 30, 2013
Collaborations
Phase 1
Minimum
Jun. 30, 2013
Collaborations
Phase 1
Maximum
Jun. 30, 2013
Collaborations
Phase 2
Minimum
Jun. 30, 2013
Collaborations
Phase 2
Maximum
Jun. 30, 2013
Collaborations
Phase 3
Minimum
Jun. 30, 2013
Collaborations
Phase 3
Maximum
Jun. 30, 2013
Collaborations
Regulatory milestones
Minimum
Jun. 30, 2013
Collaborations
Regulatory milestones
Maximum
Jun. 30, 2013
Collaborations
Commercialization milestones
Jun. 30, 2013
Collaborations
AstraZeneca
Dec. 31, 2012
Collaborations
AstraZeneca
item
Jun. 30, 2013
Collaborations
AstraZeneca
item
Jun. 30, 2013
Collaborations
AstraZeneca
Jun. 30, 2013
Collaborations
AstraZeneca
Maximum
item
Jun. 30, 2013
Collaborations
AstraZeneca
ISIS-AR
item
Jun. 30, 2013
Collaborations
Biogen Idec
Dec. 31, 2012
Collaborations
Biogen Idec
item
Jan. 31, 2012
Collaborations
Biogen Idec
Agreement entered into in January 2012
Jun. 30, 2012
Collaborations
Biogen Idec
Agreement entered into in June 2012
Dec. 31, 2012
Collaborations
Biogen Idec
Agreement entered into in December 2012
item
Jan. 31, 2013
Collaborations
Genzyme Corporation
Mar. 31, 2013
Collaborations
Genzyme Corporation
Research and development revenue under collaborative agreements                                                            
Number of targets                                     5                 3    
Upfront fee received                                   $ 6,000,000 $ 25,000,000   $ 31,000,000         $ 29,000,000 $ 12,000,000 $ 30,000,000    
Number of drugs collaborative partner may license under the separate research program                                           3                
Number of units of accounting                                       4     1              
License revenue recognized 477,000 200,000 1,916,000 1,618,000                           2,200,000 9,300,000                      
Upfront fee deferred                                         19,500,000                  
Assumed change in estimated selling price of ISIS-STAT3 (as a percent)                                         10.00%                  
Percentage by which earned revenue from ISIS-STAT3 would change based on assumed change in estimated selling price                                         7.00%                  
Amount by which earned revenue from ISIS-STAT3 would change based on assumed change in estimated selling price                                         750,000                  
Number of collaborative agreements                                                 3          
Number of convertible notes no longer guaranteed         2                                                  
Number of categories of milestone events           3                                                
Number of stages of life-cycle of drugs           3                                                
Completion period             12 months 18 months 1 year 2 years 1 year 3 years 2 years 4 years                                
Time to prepare and submit regulatory filings                             6 months 12 months                            
Time to obtain approval                             1 year 2 years                            
Example of sales threshold as milestone event                                 1,000,000,000                          
Milestone payment recognized     $ 46,000,000                             $ 10,000,000           $ 3,500,000         $ 25,000,000 $ 25,000,000